TY - JOUR
T1 - Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia
AU - Ankenman, Ralph
AU - Salvatore, Michael F.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.
AB - AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.
UR - http://www.scopus.com/inward/record.url?scp=33847103835&partnerID=8YFLogxK
U2 - 10.1176/jnp.2007.19.1.65
DO - 10.1176/jnp.2007.19.1.65
M3 - Article
C2 - 17308229
AN - SCOPUS:33847103835
SN - 0895-0172
VL - 19
SP - 65
EP - 69
JO - The Journal of neuropsychiatry and clinical neurosciences
JF - The Journal of neuropsychiatry and clinical neurosciences
IS - 1
ER -